SciSparc's NeuroThera Labs completed internal validation of a quantum sampling workflow to enhance clinical-trial data analysis, signaling progress in applying quantum computing to drug development. Separately, Hannover Medical School started a Phase IIb site for SCI-110 in adults with Tourette Syndrome, indicating late-stage momentum. The stock slid about 20% premarket, reflecting near-term risk despite the potential longer-term upside from advanced analytics and expanded trials.
Investors cheered as SciSparc's NeuroThera received conditional TSX Venture Exchange approval to pursue a majority stake in CliniQuantum, a private Israeli analytics firm. The deal, valued at about $9.46 million in SPRC stock, could unlock quantum-enabled trial insights if completed, but closing remains subject to regulatory steps and tax rulings.
SPRC stock is surging with a volume of 58.21 million today. The company is launching 3D protein modeling using quantum computing. A new research team will develop quantum algorithms for drug discovery. SPRC aims to simulate protein dynamics with greater precision. Current stock price is up 61.88% at $6.20.
SPRC stock up 152.90% on increased volume of 30.86 million shares. SciSparc collaborates with Clearmind on novel binge behavior therapies. Clearmind has filed thirteen related patents globally for the collaboration. FDA approved SPRC's IND for Phase 2b trial on Tourette Syndrome.
